Merck announced on November 20, 2026, that sacituzumab tirumotecan met the primary endpoint of overall survival in the global Phase 3 TroFuse-015 trial. The study enrolled patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who had received at least two prior lines of systemic therapy.
At the final analysis, patients assigned to the investigational TROP2-directed antibody-drug conjugate had a statistically significant improvement in overall survival compared with those assigned to physician’s choice of chemotherapy. The trial did not meet its secondary endpoint of progression-free survival. Merck reported that this was the first global Phase 3 trial to show an overall survival benefit with a TROP2-directed antibody-drug conjugate in this population.
Marjorie Green, senior vice president and head of oncology, global clinical development of Merck Research Laboratories, stated:
“We look forward to discussing these data with regulatory authorities and sharing with the scientific community on behalf of patients who may benefit.”
TroFuse-015 Trial Design and Treatment Arms
TroFuse-015 was a randomized, open-label, multicenter Phase 3 study that enrolled 473 patients. Participants were randomized to receive sacituzumab tirumotecan or one of four chemotherapy regimens selected by their physician. The control arm included trifluridine-tipiracil, irinotecan, paclitaxel, and docetaxel.
- Sacituzumab tirumotecan was administered at 4 mg/kg on days 1, 15, and 29 of each six-week cycle.
- Trifluridine-tipiracil was administered orally at 35 mg/m² twice daily on days 1 through 5 and 8 through 12 of each four-week cycle.
- Irinotecan was administered at 150 mg/m² on days 1 and 15 of each four-week cycle.
- Paclitaxel was administered at 80 mg/m² on days 1, 8, and 15 of each four-week cycle.
- Docetaxel was administered at 75 mg/m² on day 1 of each three-week cycle.
Overall survival was the primary endpoint. Secondary endpoints included progression-free survival, objective response rate, and duration of response. A blinded independent central review assessed progression-free survival.
Overall Survival and Secondary Outcomes
Merck described the overall survival improvement as clinically meaningful. The company reported that the survival results were generally consistent across subgroups regardless of TROP2 expression status.
- Overall survival significantly favored sacituzumab tirumotecan at the final analysis. The release did not disclose median survival by arm, a hazard ratio, a confidence interval, or a p-value.
- Progression-free survival did not meet the secondary endpoint based on blinded independent central review. Merck did not report progression-free survival estimates by arm.
- Objective response rate nominally favored sacituzumab tirumotecan. The prespecified analysis plan did not allow formal testing of this endpoint, and the release did not provide response rates for either arm.
- Duration of response was a secondary endpoint, with results pending disclosure.
Safety Findings
Merck reported that the safety profile of sacituzumab tirumotecan was consistent with findings from previously reported studies of the drug. The company observed no new safety signals. The release did not provide adverse event rates by treatment arm or details on event severity or treatment discontinuation.
The TroFuse Development Program
TroFuse-015 is the second Phase 3 study in Merck’s global TroFuse program to report a positive result. The program includes 18 ongoing global Phase 3 trials across multiple tumor types, including endometrial, bladder, breast, cervical, gastric, non-small cell lung, and ovarian cancers. These trials are evaluating sacituzumab tirumotecan as monotherapy and in combination with immunotherapies across earlier and advanced disease settings.
Kelun-Biotech developed sacituzumab tirumotecan, which uses a belotecan-derived topoisomerase I inhibitor as its payload. Under the companies’ licensing agreement, Merck holds exclusive rights to develop, manufacture, and commercialize the drug outside Greater China.
Merck said it plans to present the TroFuse-015 data at an upcoming medical meeting and share the findings with regulatory authorities. The company did not identify the meeting or provide a timeline for a regulatory submission. The presentation will be the next opportunity to assess the magnitude of the survival benefit alongside the detailed efficacy and safety results for both treatment arms.
You can also read: TroFuse-005 at ESMO 2026: Sacituzumab Tirumotecan Significantly Improves Overall Survival in Advanced Endometrial Cancer.

